Tumor Scintigraphy

Aetna covers ProstaScint for preoperative staging of biopsy‑proven prostate cancer with moderate-to-high risk of occult extra‑prostatic metastasis and for staging suspected recurrence after prostatectomy or radiation, and covers Oncoscint (satumomab pendetide) to detect occult colorectal carcinoma when CEA is elevated but conventional imaging is negative, to evaluate solitary-site recurrences prior to potentially curative resection, and to detect recurrent ovarian cancer when tumor markers rise and other exams/imaging cannot locate disease. Other uses are excluded: CEA‑Scan, AdreView (I‑123 iobenguane) beyond pheochromocytoma/neuroblastoma, lymphoscintigraphy/SLNB and MIBG I‑123 for non‑oncologic cardiac conditions, and Oncoscint immunoscintigraphy for off‑label cancer screening or detection are considered experimental/investigational.

"Parathyroid localization enhanced by dual-isotope subtraction and/or ultrasound with iPTH assay in US-guided FNA: documentation of ultrasound and iPTH aspirate results when performed to direct surg..."